Trials / Active Not Recruiting
Active Not RecruitingNCT07362264
A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors
An Open, Multicenter, Phase I Clinical Study on the Safety, Efficacy, and Pharmacokinetics of SH006 Injection Combination in Patients With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of the combination therapy of SH006 injection in patients with advanced solid tumors
Detailed description
This is an open-label, multicenter study to evaluate the safety and efficacy of SH006 injection (15 mg/kg/30 mg/kg) in combination with bevacizumab/oxaliplatin/capecitabine in the treatment of patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SH006 | The dosage of SH006 is 15 mg/kg Q3W or 30 mg/kg Q3W, with a treatment cycle of 21 days |
Timeline
- Start date
- 2025-07-01
- Primary completion
- 2026-12-30
- Completion
- 2028-12-30
- First posted
- 2026-01-23
- Last updated
- 2026-01-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07362264. Inclusion in this directory is not an endorsement.